dr. kerrigan on remaining challenges in alk nsclc
Published 4 years ago • 209 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
0:59
dr. kerrigan on remaining challenges in ros1 nsclc
-
0:59
dr. kerrigan on design and findings of the profile 1001 trial in ros1-mutated nsclc
-
1:32
dr. stinchcombe on remaining challenges in alk nsclc
-
1:41
dr. pennell on remaining challenges in nsclc
-
6:04
case study: progression on alk inhibitors in nsclc
-
0:52
dr. rotow on remaining questions with brigatinib in alk nsclc
-
0:53
dr. stinchcombe discusses differences in toxicity profiles among alk inhibitors in nsclc
-
1:57
dr. shaw on sequencing strategies in alk-positive nsclc
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
0:59
dr. johung on prognosis of patients with alk-rearranged nsclc and brain metastases
-
1:02
dr. mok on overall survival data from the alex trial in alk lung cancer
-
1:02
dr. rotow on the implications of next-generation alk inhibitors in nsclc
-
0:41
dr. gandhi discusses the role of alectinib in alk lung cancer
-
1:07
dr. massarelli on first-line alk nsclc treatment
-
1:39
dr. raez on resistance mechanisms in alk nsclc
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
1:47
dr. paik on resistance mutations in nsclc
-
2:16
dr. shaw discusses efficacy of lorlatinib in alk nsclc
-
1:54
dr. gainor on the pacific-2 trial in stage iii nsclc